Relx (LON:REL) PT Lowered to GBX 2,185
Relx (LON:REL) had its price objective reduced by Goldman Sachs Group from GBX 2,302.81 ($30.29) to GBX 2,185 ($28.74) in a report released on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. Goldman Sachs Group’s price target would indicate a potential upside of 42.35% from the company’s previous close.
Other research analysts have also recently issued reports about the stock. Citigroup raised shares of Relx to a “buy” rating in a report on Tuesday, January 21st. Morgan Stanley boosted their price objective on shares of Relx from GBX 1,830 ($24.07) to GBX 2,250 ($29.60) and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Berenberg Bank cut shares of Relx to a “hold” rating and decreased their price objective for the company from GBX 2,120 ($27.89) to GBX 2,100 ($27.62) in a report on Friday, February 14th. Deutsche Bank reissued a “hold” rating on shares of Relx in a report on Friday, February 14th. Finally, Liberum Capital reissued a “buy” rating on shares of Relx in a report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 2,066.30 ($27.18).
Relx stock traded up GBX 30 ($0.39) during trading hours on Tuesday, hitting GBX 1,535 ($20.19). The stock had a trading volume of 7,189,369 shares, compared to its average volume of 4,990,000. The company has a quick ratio of 0.33, a current ratio of 0.41 and a debt-to-equity ratio of 293.11. The stock has a market capitalization of $29.67 billion and a P/E ratio of 19.96. Relx has a 12-month low of GBX 1,597 ($21.01) and a 12-month high of GBX 2,109 ($27.74). The stock’s 50-day moving average price is GBX 1,922.01 and its 200-day moving average price is GBX 1,894.44.
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Featured Story: How to calculate compound interest
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.